5 completed, 2 active not recruiting, 1 not yet recruiting. 8 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 5, Active not recruiting 2, Not yet recruiting 1 |
| Phase 1 | 4 | Completed 2, Active not recruiting 1, Not yet recruiting 1 |
Follow Pancytopenia: new trials by email Literature Review of Pancytopenia trials Research Report on Pancytopenia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1/2 Study to Evaluate the Safety and Efficacy of Dibotatug (DR-01) in Adults With Bone Marrow Failure Syndromes Dibotatug (DR-01) - Bone Marrow Failure Syndromes, Aplastic Anemias | Phase 1 / Phase 2 | Not yet recruiting | Dren Bio | 60 | 2026-08-01 | 2026-07-24 |
| Eltrombopag for Fanconi Anemia Eltrombopag - Fanconi Anemia | Phase 2 | Active not recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 25 | 2018-11-02 | 2026-09-16 |
| Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A in Naive Aplastic Anemia (AA) Subjects Eltrombopag, Rabbit ATG, CsA - Aplastic Anemia | Phase 2 | Completed | Novartis Pharmaceuticals | 10 | 2015-05-12 | 2019-07-26 |
| A Study to Assess the Safety and Efficacy of Eltrombopag in Japanese Subjects With Refractory, Moderate or More Severe Aplastic Anemia Eltrombopag 12.5 mg, Eltrombopag 25 mg - Cytopaenia | Phase 2 | Completed | Novartis Pharmaceuticals | 21 | 2014-07-23 | 2019-05-03 |
| Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia Cohort 1: hATG, CsA, EPAG Day 14 to Month 6, Cohort 2: hATG, CsA, EPAG Day 14 to Month 3, Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6 - Severe Aplastic Anemia | Phase 1 / Phase 2 | Active not recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 207 | 2012-07-02 | 2026-04-13 |
| Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic Anemia Cyclophosphamide, Cyclosporine - Aplastic Anemia, Neutropenia | Phase 1 / Phase 2 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 22 | 2010-08-01 | 2017-05-22 |
| A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia Cyclophosphamide, Fludarabine - Aplastic Anemia, Neutropenia | Phase 1 / Phase 2 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 1 | 2010-08-01 | 2021-07-02 |
| Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia Anti-thymocyte globulin (rabbit), Anti-thymocyte globulin (horse), Cyclosporine - Immunosuppresion, Thrombocytopenia | Phase 2 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 136 | 2005-11-28 | 2017-06-08 |
Anemia, Aplastic (7) · Autoimmune Diseases (3) · Neutropenia (3) · Thrombocytopenia (3) · Leukopenia (2) · Bone Marrow Failure Disorders (1) · Fanconi Anemia (1) · Hematologic Diseases (1) · Inflammation (1) · Jacobs syndrome (1) · Leukocyte Disorders (1) · Recurrence (1)
Anemia (8) · Bone Marrow Diseases (8) · Cytopenia (8) · Hemic and Lymphatic Diseases (8) · Bone Marrow Failure Disorders (7) · Hematologic Diseases (7) · Leukocyte Disorders (5) · Agranulocytosis (3) · Blood Platelet Disorders (3) · Immune System Diseases (3) · Leukopenia (3) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Anemia, Aplastic (1) · Anemia, Hypoplastic, Congenital (1)
eltrombopag (4) · Cyclosporine (3) · Cyclophosphamide (2) · Alemtuzumab (1) · Antilymphocyte Serum (1) · Cyclosporins (1) · Influenza Vaccines (1) · fludarabine (1) · thymoglobulin (1)
National Heart, Lung, and Blood Institute (NHLBI) (5) · Novartis Pharmaceuticals (2) · Dren Bio (1)
United States (6) · Japan (2)
Danielle M Townsley, M.D. (3) · Andre Larochelle, M.D. (1) · Neal S Young, M.D. (1) · Wan-Jen Hong, MD (1)
PMID 34724566, PMID 29674506, PMID 29958797, PMID 25185712, PMID 26354756, PMID 27658437, PMID 29419434, PMID 31183813, PMID 33410523, PMID 33910334, PMID 34525188